Clinical Trial Update: Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for romosozumab in postmenopausal women with low bone mineral density/postmenopausal osteoporosis; results have been posted after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopause Bone Mineral Density Disorders

Drugs mentioned

• Romosozumab (romosozumab)

Snippet

Sponsor: Amgen | Conditions: Low Bone Mineral Density, Postmenopausal Osteoporosis | Phase 2 | Status: COMPLETED | Results posted: 2018-12-14